Jefferies keeps EUR 16 target for Almirall stock

Published on 10/08/2026 at 18:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

First-half 2026 sales rose 7.50 percent to EUR 602.70 million. Almirall stock costs EUR 10.07 on October 8, 2026 after EUR 10.27, minus 1.95 percent.

Key points in brief

Jefferies maintained a EUR 16.00 price target and Buy rating for Almirall on October 8, 2026.
Almirall stock was at EUR 10.07 at Lang & Schwarz, down 1.95 percent from the EUR 10.27 prior close.
First-half 2026 net sales rose 7.50 percent to EUR 602.70 million, while EBITDA increased 23.70 percent.
Almirall will publish nine-month 2026 results on November 9, 2026.

Pop-Art-Comic einer Dermatologin, die mit Lupe die Haut einer Patientin untersucht — Almirall S.A. (ES0157097017) inspiriert Pop-Art-Comic-Szene einer Dermatologin bei Hautuntersuchung mit Lupe, farbenfroh, Illustration mit AI erstellt.

Almirall (ISIN ES0157097017) was at EUR 10.07 at Lang & Schwarz on October 8, 2026 at 6:09 p.m. CEST, down 1.95 percent from the EUR 10.27 prior close. On October 8, 2026, Bolsamania reported that Jefferies reiterated its Buy rating and maintained a EUR 16.00 price target.

What does the EUR 16 target imply?

The target lies 58.89 percent above the Lang & Schwarz price. Jefferies linked its view to an expected reacceleration of Ebglyss growth in the third quarter after order volatility among German wholesalers in the second quarter.

The estimate also highlights a counter-factor. Jefferies said German pharmaceutical rebate reform could raise discounts from 7.00 percent to 15.50 percent from 2027, with a potential 8.00 percent to 10.00 percent EBITDA impact during 2027-2034.

Three milestones shape the story

On February 23, 2026, Almirall reported 12.40 percent net sales growth for fiscal 2025 on its investor page. On July 24, 2026, Almirall reported first-half 2026 net sales of EUR 602.70 million, up 7.50 percent year over year, and EBITDA of EUR 150.70 million, up 23.70 percent.

On October 8, 2026, Jefferies maintained the EUR 16.00 target. The sequence matters because the latest valuation view now sits against reported growth in both sales and profitability.

Clinical evidence adds a second driver

On September 30, 2026, Finanznachrichten published Almirall's EADV 2026 program, which included more than 20 abstracts. Separate EADV data showed 92.90 percent of patients achieved an EASI-75 response at week 108 in the ADlong study.

Almirall's investor calendar lists nine-month 2026 financial results for November 9, 2026 and fiscal-year 2026 results for February 22, 2027, according to Almirall. Those dates offer the next quantified checks on Ebglyss growth, German rebate exposure and the 2026 outlook.

Almirall stock falls below EUR 11

The after-hours Lang & Schwarz quote of EUR 10.07 on October 8, 2026 was EUR 0.20 below the prior close of EUR 10.27, a minus 1.95 percent move. Market capitalization was EUR 2.2 billion, while the 52-week range was EUR 10.02 to EUR 13.98.

The further course of trading is shown by the continuously updated real-time quote of Almirall stock.